PLoS ONE (Jan 2020)

Clinical stage provides useful prognostic information even after pathological stage is known for prostate cancer in the PSA era.

  • Maxine M Chen,
  • Jaquelyn L Jahn,
  • John R Barber,
  • Misop Han,
  • Meir J Stampfer,
  • Elizabeth A Platz,
  • Kathryn L Penney

DOI
https://doi.org/10.1371/journal.pone.0234391
Journal volume & issue
Vol. 15, no. 6
p. e0234391

Abstract

Read online

BackgroundPathological and clinical stage are associated with prostate cancer-specific survival after prostatectomy. With PSA screening, the post-surgery prognostic utility of clinical stage is debatable in studies seeking to identify new biomarkers. Few studies have investigated clinical stage and lethal prostate cancer association after accounting for pathological stage. We hypothesize that clinical stage provides prognostic information beyond pathological stage in the PSA era.MethodsCox regression models tested associations between clinical and pathological stage and lethal prostate cancer among 3,064 participants from the Health Professionals Follow-Up Study and Physicians' Health Study (HPFS/PHS) who underwent prostatectomy. Likelihood ratio tests and c-statistics were used to assess the models' prognostic utility. Equivalent analyses were performed in 16,134 men who underwent prostatectomy at Johns Hopkins.ResultsIndependently, clinical and pathological stage were associated (pConclusionsDespite stage migration resulting from widespread PSA screening, clinical stage remains associated with progression to lethal prostate cancer independent of pathological stage. Future studies evaluating associations between new factors and poor outcome following prostatectomy should consider including both clinical and pathological stages since the data is already available.